Objective To determine whether a monogenic basis explains sudden infant death syndrome (SIDS) using an exomewide focus.
Conclusions
The lack of exome-wide significant genetic associations indicates an extreme heterogeneity of etiologies underlying SIDS. Our approach to understanding the genetic mechanisms of SIDS has far reaching implications for the SIDS research community as a whole and may catalyze new evidence-based SIDS research across multiple disciplines. Perturbations in glucocorticoid biosynthesis may represent a novel SIDSassociated biological pathway for future SIDS investigative research. (J Pediatr 2018; 203:423-8) .
S udden infant death syndrome (SIDS) is the sudden unexpected death that remains unexplained despite comprehensive clinical and pathologic investigations. 1 SIDS represents 70%-80% of all sudden unexpected infant deaths, with an incidence of 0.4 per 1000 live births in the United Kingdom and 0.5 per 1000 live births in the US. 2, 3 The peak incidence occurs between 2 and 4 months of age and is more common in male infants. It is associated commonly with environmental risk factors such as co-sleeping or the prone sleeping position. 4 Despite successful targeted risk-reduction campaigns, the number of SIDS cases has plateaued. SIDS, also referred to as sudden unexplained infant death, remains the leading cause of postneonatal mortality. 4 A triple-risk model for SIDS suggest the convergence of the vulnerable infant in the setting of exogenous stressors occurring in a critical development period. 5 Although many pathophysiologic theories have been proposed, decisive pathogenic substrates/mechanisms triggering an infant's sudden death remain unclear. [6] [7] [8] [9] Several studies have implicated both common and rare genetic variants involved in autonomic function, neurotransmission, energy metabolism, response to infection, and cardiac repolarization. [10] [11] [12] [13] [14] Potentially lethal inherited genetic heart diseases including long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, and hypertrophic cardiomyopathy have been implicated as monogenic causes for a small proportion (<10%) of SIDS cases. 10, 13, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] 
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However, <100 investigations of genetic variation in population-based SIDS cohorts have been published to date. These studies are largely based on hypothesis-driven, candidate gene/pathway approaches that recognize established environmental risk factors for SIDS, with an average cohort size of just 125 SIDS cases. 13 Although one may postulate that the genetics of SIDS are most likely multigenic and complex, no studies have attempted to elucidate the underlying genetic basis in a single SIDS cohort across multiple biological pathways in an unbiased manner. Here, using whole-exome sequencing (WES), we conducted an exome-wide analysis of rare proteinaltering variation followed by biological Ingenuity Pathway Analysis (IPA) in a cohort of nearly 300 unrelated white SIDS cases.
Methods
As previously described, the SIDS cohort (N = 427) consisted of 95 coroners' cases from the United Kingdom (London, Sheffield, Edinburgh, and Bristol) and 332 coroner/medical examiner/forensic pathologist-referred cases collected from 6 ethnically and geographically diverse US populations. 28 Because of the lack of uniformity in procedures and reporting between medical examiner offices in the US, differences in protocols may exist. Nonetheless, both gross and histologic examinations of all major organs were performed and all cases satisfied our enrollment criteria, which included sudden unexplained death of an infant <1 year of age, European descent, and a comprehensive negative medicolegal autopsy, including a negative toxicology screen and death scene investigation. Infants who clearly demonstrated to have experienced asphyxia or specific disease-causing death were excluded. Ethnicity was selfreported by the referring coroner/medical examiner. This anonymous necropsy study only had limited medical information such as the sex, ethnicity, age at the time of death, and sleep position available. This study complies with the Declaration of Helsinki; locally appointed ethics committees, including Mayo Clinic's institutional review board, approved the research protocol.
Control Population
White control exomes (509 female, 464 male) from the ICR1000 UK exome sequencing of the 1958 Birth Cohort study were included for analysis. 29 As previously reported, exome sequencing was performed using the Illumina TruSeq and Illumina instruments (Illumina, Inc, San Diego, California).
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Whole-Exome Sequencing Genomic DNA isolated from each SIDS case underwent WES at the KCL-GSTT Biomedical Research Centre Genomics Platform, London, United Kingdom, or Mayo Clinic's Medical Genome Facility, Rochester, Minnesota, as described previously. 28 Cases were excluded from further analysis if <75% of the Gencode-defined protein coding exome was covered by <20 reads. A set of 3847 common variants located outside of regions of the genome, where there is extensive linkage disequilibrium, were used to estimate relatedness within the study cohort. To avoid potential confounding due to population stratification, ancestry estimation was undertaken using the first 2 dimensions of multidimensional scaling using Euclidean distance undertaken with the King software package (Center for Public Health Genomics, University of Virginia, Charlottesville, Virginia). Quality control metrics excluded 7 cases. 28 The resulting SIDS cases (N = 278) and European controls (N = 973) that formed a homogeneous cluster on the first 2 principal components were included in the case-control rare variant analysis.
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Exome-Wide Rare Variant Analysis
The 278 European white SIDS cases and 973 ethnic-matched controls underwent a case-control simple collapsing exomewide rare variant association analysis using the Efficient and Parallelizable Association Container Toolbox. 30 Cases and controls were coded with a binary indicator according to the presence/absence of a "qualifying" variant in each gene based on 6 genetic models: dominant nonsynonymous (amino acid altering), dominant nonsynonymous-combined annotationdependent depletion (CADD ≥20: equivalent to a probability of 0.99 that the variant has a functional impact. 31 ), dominant putative loss-of-function (ie, nonsense, frame-shift, and canonical splice-site errors), recessive nonsynonymous, recessive nonsynonymous-CADD ≥20, and recessive putative loss-of-function.
For all models, only "ultra-rare" variants with a minor allele frequency <0.00005 (1:20 000 alleles) derived from the Exome Aggregation Consortium 32 were included. Deviation from the null model of no excess of rare variation in cases was evaluated with a 1-tailed Fisher exact test. Despite being too stringent, a Bonferroni-adjusted P value threshold of < 2.5 × 10
−6
was considered as exome-wide significant.
Ingenuity Pathway Analysis
An IPA was used to analyze a list of 405 genes (P < .05) obtained by performing an exome-wide rare variant comparative analysis between European SIDS cases and ethnic-matched controls. IPA is a Web-based tool that is used for discovery and visualization of significant pathways and networks and close correlations with disease and functional classes. Data were analyzed with QIAGEN's IPA (QIAGEN Redwood City, California; www.qiagen.com/ingenuity) using default analysis settings.
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Statistical Analyses
Categorical variables were expressed as absolute numbers and percentage and compared with the Fisher exact or c 2 tests. Probability values were based on 2-sided tests considered significant at P < .05. Analysis was conducted with SPSS, version 18.0, software (SPSS, Chicago, Illinois).
The significance of the association between the data set (ie, 405 "SIDS genes") and the IPA canonical pathway was measured as a ratio of the number of genes from the data set that map to the pathway divided by the total number of genes that map to the canonical pathway. The Fisher exact test righttailed was used to calculate a P value determining the probability that the association between the genes in the dataset and the canonical pathway is explained by chance alone.
Results
The cohort consisted of 278 cases (173 male infants, 105 female infants; average age = 2.7 ± 1.98 months). The epidemiologically high-risk age group of 2-4 months (55.4%) and male sex (62.9%) accounted for the majority of the cases. Sleep characteristics were known in 60% of the cohort (Table I) . Exome-wide rare variant analyses were performed with the 278 European ancestry cases and 973 matched controls. None of the estimated 20 000 genes within the human genome were associated with SIDS when we considered an exome-wide significant P value threshold of <2.5 × 10 −6 with any of the 6 aforementioned inheritance models.
There were 405 genes with potential case:control, ultrarare (minor allele frequency <0.00005), nonsynonymous variant over-representation at P < .05 threshold ( Table II ; available at www.jpeds.com) with 17 genes reaching P < .005 (Table III) . Online Mendelian Inheritance in Man disease 34 and PathCards SuperPathway 35 associations for each gene is listed in 
Ingenuity Pathway Analysis
IPA was performed on the aforementioned 405 genes from our dominant nonsynonymous ultra-rare variants analysis with a P value <.05. IPA identified 5 canonical pathways with a P < .05 (Table VI) . The top canonical pathway involved glucocorticoid biosynthesis (P = .0107, 
Discussion
We report genetic insights derived from WES in a large cohort of unrelated SIDS cases. We used a first ancestry matched casecontrol burden analysis of ultra-rare variants involving nearly 300 cases and 1000 healthy controls to identify potential novel monogenic causes for SIDS. Although no genes reached the very strict Bonferroni-corrected, exome-wide significance threshold of P < 2.5 × 10
, 405 genes showed a potential overrepresentation of ultra-rare, nonsynonymous variants. However, variants were observed in <2% of the SIDS cohort for 90% of these 405 genes. This confirms previous speculation that SIDS is a highly heterogeneous condition and likely results from a complex interplay of genetic and environmental factors rather than from a small number of highly penetrant monogenic disorders. In addition, at the P value threshold of P < .05, one might expect 1000 genes to surface as seemingly overrepresented in cases just by chance (ie, 20 000 genes divided by 20). In other words, this study strongly suggests that the vast majority of SIDS is not monogenetically mediated at least by ultra-rare genetic variation localizing to the exome. Although it remains to be confirmed or refuted, much of SIDS may not have a genetic component at all.
Nevertheless, some of these genes identified are appealing pathobiologically and could represent novel, monogenic causes for a small minority of SIDS cases. For example, there was potential over-representation (P < .005) of NR3C2, CHRM3, and LHX9 variants in SIDS cases compared with controls. These 3 genes may represent biologically plausible candidates for SIDS pathogenicity that could account independently for a small subset of SIDS cases (~2%).
The NR3C2 gene encodes for a mineralocorticoid receptor that mediates aldosterone activity and is responsible for autosomal-dominant pseudohypoaldosternism type 1, which is a rare disorder characterized by renal resistance to aldosterone, with salt-wasting, hyperkalemia, and metabolic acidosis. 36 If undetected and untreated, autosomal-dominant pseudohypoaldosternism type 1 may present with neonatal lethality as the result of severe hyponatremia, metabolic acidosis, or hyperkalemia-mediated arrhythmia and cardiorespiratory arrest. 37, 38 Interestingly, conditional targeted cardiomyocyte overexpression of mineralocorticoid receptor in mice leads to early sudden death without cardiac structural alteration as a result of prolonged ventricular repolarization and spontaneous and triggered ventricular arrhythmias associated with ion channel remodeling. The CHRM3 gene encodes for cholinergic receptor muscarinic 3 (M3-receptor). Muscarinic acetylcholine receptors are G-protein-coupled receptors that play a key role in parasympathetic acetylcholine neurotransmission for a variety of physiological functions within the brain, heart, and respiratory system. 40 In the respiratory system, muscarinic M3-receptors mediate smooth muscle contraction for respiration. 40 In the heart, M3-receptors may play a role in the regulation and maintenance of cardiac function. 41, 42 The M3-receptors activate the delayed rectifying potassium current IKM3 to participate in the regulation of heart rate, cardiac resting membrane potential, and cardiac repolarization. 43 The M3-receptor also interacts with gap-junctional channel connexin 43 to maintain cell-cell communication and excitation propagation in the heart. 44 Interestingly, connexin 43 mutations leading to gap junction loss were implicated previously in some cases of SIDS. 24 In 2010, cardiac muscarinic receptor overexpression in left ventricular heart samples was shown to be associated with SIDS. 45 In 1995, Kinney et al provided evidence that deficiency of muscarinic receptor binding in the arcuate nucleus of the medulla may be associated with an increase in the probability of death from SIDS.
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LHX9-encoded Lhx9 is a member of the apterous group of the LIM-homeodomain family of evolutionary conserved transcription factors crucial for the correct development of many organs including the heart and the nervous system, including the forebrain, thalamus, hypothalamus, and pineal gland. [47] [48] [49] [50] [51] Sparks and Hunsaker reported a significant reduction in the size of the pineal gland in SIDS cases compared with controls. 52 In mice, Lhx9 expression is maintained after birth in the hippocampal formation and restricted to the dentate gyrus. 51 Recently, Kinney et al identified dentate gyrus abnormalities as a potential developmental vulnerability in sudden unexplained death in infants that may lead to autonomic/respiratory instability or autonomic seizures and sleep-related sudden death of the vulnerable infant when exposed to homeostatic stressors. 53, 54 Whether NR3C2, CHRM3, LHX9, or any of the other genes that may have an over-representation of ultra-rare, nonsynonymous variants in SIDS are indeed responsible for the pathogenic basis for SIDS will require substantial functional analyses and replication studies before being considered as a new pathogenic substrate for some infant deaths.
IPA has suggested a potential association between the glucocorticoid biosynthesis signaling pathways and SIDS. Glucocorticoids and mineralocorticoid, such as aldosterone and cortisol, are hormones that regulate numerous physiological processes, including intermediate metabolism, immune function, and cardiovascular function. 55, 56 They are synthesized and released from the adrenal gland in a circadian manner and in response to stress. Nearly 3.5% of the white European cases had a heterozygote, ultra-rare, nonsynonymous variant within either the CYP17A1 or CYP11B2 compared with 0.4% of controls. Although the CYP17A1-encoded steroid 17-alphahydroxylase is involved in the synthesis of cortisol, the CYP11B2-encoded aldosterone synthase is involved in the synthesis of aldosterone. 55 Aldosterone, through increased activation of the mineralocorticoid receptor, increases calcium influx in ventricular myocytes, prolongs ventricular repolarization, and leads to triggered cardiac arrhythmias. 57 Additional investigation and replication will be necessary before invoking genetic perturbations in glucocorticoid biosynthesis signaling as a potentially novel pathogenic substrate for SIDS.
From the perspective of ultra-rare genetic variation in the exome, the lack of significant genetic associations suggests an extreme heterogeneity of etiologies underlying SIDS. Until or unless some of the genes identified herein emerge as true SIDS-susceptibility genes with sufficient monogenic penetrance, then monogenic SIDS, stemming from the cardiac channelopathies and other established sudden death predisposing pathways, comprises <10% of all SIDS. We conclude that the vast majority of SIDS is not monogenic, at least within the exome. Whether oligo/polygenic models of genetic variation that account for the "vulnerable infant" will emerge remains to be determined. ■
We thank both the medical examiners and coroners for referring the victims of sudden death to our program in an effort to find an explanation for their demise.
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